Ultragenyx (RARE)
Healthcare
Biotechnology
25.00 $
+0.4%
vs. previous close
Closing price · As of: 3. Aug 2026
Ultragenyx (RARE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -466 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -45 | -106 | -161 | -254 | -291 | -345 | -132 | -339 | -380 | -475 | -414 | -466 | |
| 0.7 | 1.4 | 3.4 | 5.8 | 20 | 8.5 | 12 | 13 | 18 | 26 | 36 | 35 | |
| 5.4 | 25 | 48 | 68 | 80 | 82 | 86 | 105 | 130 | 135 | 158 | 153 | |
| 8.7 | 31 | 55 | 63 | -85 | 83 | 0.9 | 0.2 | 75 | – | – | – | |
| 2.2 | 7.7 | 26 | -20 | -25 | -16 | 105 | -63 | 60 | -15 | 14 | -23 | |
| 2.1 | 5.0 | 10 | 2.8 | 4.1 | 25 | 44 | 73 | 146 | 47 | 7.5 | 6.0 | |
| -123 | -292 | 90 | 56 | -33 | -13 | -179 | -195 | -292 | 168 | -18 | 236 | |
| 4.3 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | |
| 189 | 468 | 87 | 141 | 299 | 340 | 525 | 40 | 11 | – | – | – | |
| -4.9 | -4.9 | -4.9 | -4.9 | – | – | – | – | – | – | – | – | |
| 185 | 468 | 139 | 136 | 337 | 679 | 600 | 119 | 501 | 388 | 399 | 478 | |
| 17 | 69 | 68 | -61 | 12 | 321 | 290 | -417 | -172 | 82 | -35 | 253 | |
| -47 | -111 | -171 | -257 | -295 | -370 | -176 | -412 | -527 | -522 | -422 | -472 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.